Andrew Allen, M.D., Ph.D.
President and Chief Executive Officer

Andrew Allen is a Co-Founder of Gritstone Oncology and serves as President, Chief Executive Officer and a member of the Board of Directors. Dr. Allen was a Co-Founder of Clovis Oncology (NASDAQ: CLVS)  and served as Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer from the time of the company’s inception in 2009 until July 2015. Prior to that, Allen was Chief Medical Officer at Pharmion Corporation, which was sold to Celgene Corporation in 2008 for $2.9 billion, following the development of Vidaza™ for the treatment of myelodysplastic syndromes and Thalomid™ for the front-line treatment of multiple myeloma. Allen also served previously in Clinical Development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company in London and New Jersey, advising life science companies on strategic issues.  Allen trained in Medicine at Oxford University and obtained a Ph.D. in Immunology at Imperial College, London. He currently serves on the board of directors of Epizyme (NASDAQ: EPZM), and Cell Design Labs (San Francisco, CA) and advises Epic Sciences (La Jolla, CA).


Karin Jooss, Ph.D.
Executive Vice President of Research and Chief Scientific Officer

Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology.  Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years.  While at Pfizer, she built and led immuno-oncology teams, was a member of the Vaccine Immunotherapeutics leadership team and served as the head of the Immunophamacology team. Her duties included overseeing the assessment of all cancer vaccine in-licensing opportunities, and developing and launching Pfizer’s first clinical cancer vaccine program deploying a variety of vaccine platforms and immune modulators to build a multi-component vaccine-based immunotherapy regimen. Prior to joining Pfizer, Jooss served as vice president of Research at Cell Genesys, Inc. where she oversaw all research activities related to the company’s cancer vaccine and oncolytic virotherapy programs. Jooss received her Ph.D. in Molecular Biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania. She is on the editorial board of Molecular Therapy and Journal of Gene Medicine and is a member of the immunology and educational committee for the American Society of Gene Therapy as well as the Industry Task Force of the Society for Immunotherapy of Cancer (SITC).


Roman Yelensky, Ph.D.
Chief Technical Officer

Roman Yelensky serves as Chief Technical Officer, responsible for overseeing the company’s genomics, proteomics and informatics programs. He joined Gritstone at its inception in October 2015 as executive vice president of sequencing and bioinformatics. Prior to that, he was vice president of biomarker and companion diagnostic development at Foundation Medicine, which he joined at its inception. While at Foundation Medicine, he co-led sequence data analysis for FoundationOne™ and led validation studies supporting clinical laboratory accreditation and testing of >100,000 patients. Dr. Yelensky established Foundation Medicine’s FDA-regulated products program, leading to the FDA approval of FoundationFocus CDxBRCA, the first NGS-based companion diagnostic. He also contributed to key national initiatives on the clinical implementation of next-generation sequencing (NGS), leading the diagnostic implementation of Lung-MAP, a first-of-its-kind NCI-sponsored trial matching lung cancer patients to investigational treatments using comprehensive genomic testing. Prior to Foundation Medicine, Dr. Yelensky was a senior scientist in biomarker development at Novartis. He has co-authored more than 75 manuscripts on bioinformatics, statistical genetics, NGS biomarker and assay development and cancer genomics. He earned an M.S. in computer science from Stanford University and a Ph.D. in bioinformatics and integrative genomics from the Harvard-MIT Division of Health Sciences and Technology.


Matthew Hawryluk, Ph.D.
Executive Vice President and Chief Business Officer

Matthew Hawryluk serves as Executive Vice President and Chief Business Officer, and leads partnering activities at Gritstone. Dr. Hawryluk joined Gritstone after serving as the Vice President of Corporate and Business Development at Foundation Medicine (NASDAQ: FMI), where he led the Biopharmaceutical business and a team responsible for business development, strategic alliances, and operations. Hawryluk forged partnerships with dozens of biopharma companies over more than four years, providing comprehensive genomic profiling for clinical trials, molecular information, and companion diagnostics. Previously, he held roles in business development, marketing, and product management across multiple divisions of Thermo Fisher Scientific. Hawryluk holds a Ph.D. in Cell Biology and Protein Biochemistry from the University of Pittsburgh School of Medicine, and completed his MBA at Carnegie Mellon University’s Tepper School of Business as a Swartz Entrepreneurial Fellow.

Raphael Rousseau.jpg

Raphaël F. Rousseau, M.D., Ph.D.
Chief Medical Officer

Raphaël Rousseau serves as Chief Medical Officer, responsible for leading the development of Gritstone’s cutting-edge neoantigen immunotherapy platform. He has experience in both the biotechnology industry and academia. He also has extensive expertise in innovative study designs and in Phase 1-3 studies of targeted therapies, including small molecule inhibitors, monoclonal antibodies, gene-modified immune effector cells and vaccines, and nanosize vectors. Prior to Gritstone, he spent eight years at Genentech, a member of the Roche group, where he held positions of increasing responsibility. Dr. Rousseau created the innovative Pediatric Oncology Drug Development (iPODD) team and the pediatric franchise at Roche-Genentech, a unique approach to pediatric drug development in the pharma industry. As global franchise head, pediatrics, in the Product Development Oncology division, he managed a clinical team of physicians and scientists across sites as well as a cross-functional development and study management team of more than 60 people across several key functions, including clinical science, safety, regulatory, research, biomarkers, clinical pharmacology and operations. He served as chair of the Development Review Committee for pediatric oncology, reviewing and making decisions about early- and late-stage compounds across the Roche-Genentech oncology portfolio. He also launched the iMATRIX master trial concept, an innovative Phase 1-2 multi-tumor, multi-drug collaborative drug development platform for patients with high-risk pediatric malignancies. Before Genentech, Dr. Rousseau was international medical leader, hematology at Roche. Before joining Roche in 2009, Dr. Rousseau was a professor of medical and pediatric oncology at the Université Claude Bernard in Lyon, France. At the Léon Bérard Comprehensive Cancer Center in Lyon, Dr. Rousseau was head of the pediatric translational research program where he created and led the first European consortium for the conduct of an EMA-approved phase 1 study using CD19-targeting CAR T cells for the treatment of pediatric high-risk leukemias. Earlier in his career, he was a clinical fellow at Texas Children’s Cancer Center and a research fellow at the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, where he co-developed a translational, GMP-grade, FDA-approved antitumor approach using genetically-modified autologous and allogeneic tumor cells to treat high-risk pediatric acute leukemias, chronic lymphocytic leukemia and neuroblastoma. He earned a Ph.D. in therapeutic biotechnologies at the Université Denis Diderot and an M.D. from Université René Descartes, both in Paris. He is board certified in pediatrics and has a sub-specialty certification in pediatric hematology-oncology.


Erin E. Jones, M.S.
Senior Vice President and Global Head of Regulatory Affairs and Quality Assurance

Erin Jones serves as Senior Vice President and Global Head of Regulatory Affairs and Quality Assurance. Prior to Gritstone, Jones served as Global Head of Regulatory, Medical Writing, and Pharmacology/Toxicology at Puma Biotechnology, in support of neratinib’s late stage development.  While at Genentech, Jones held a variety of positions including Head of Regulatory Intelligence and HER Franchise Regulatory Group Leader, where he oversaw late-stage development, BLA submissions, and ODAC preparations for Kadcyla™ and Perjeta™ in HER2-positive metastatic breast cancer, and led approvals for Herceptin™ in HER2-positive adjuvant breast and gastric cancers. Additionally, Jones has directed the regulatory development of dozens of small-molecules, monoclonal antibodies, antibody-drug conjugates, plasmids, adenoviral gene therapies, and companion diagnostics in oncology and hematology at Genentech, BioMarin, Cephalon, and Centocor. Jones received his MS in Computer Systems at Pennsylvania State University.